3 years ago

Kynos Therapeutics Raises £9M for Immune-Metabolic Therapeutics

  • Kynos Therapeutics, an immune-metabolic company, has raised £9M in funding

  • The company will use the funds to expand operations and its development efforts, including financing its lead KMO inhibitor programme through Phase 1 clinical trials.

      • ProblemHealthcare

      "Kynos Therapeutics is addressing the issue of inflammation and tissue damage caused by the enzyme kynurenine 3-monooxygenase (KMO), which is crucial in regulating the immune system. The company aims to develop and test KMO inhibitors to reduce the damaging effects of KMO on cells, thereby protecting against tissue damage in critical illness post-surgery, inflammatory conditions, and cancers where inflammation hinders the immune response."

      Solution

      "Kynos Therapeutics is developing a pipeline of first-in-class KMO inhibitors to prevent tissue damage and protect cells from the harmful effects of KMO. These inhibitors are designed to reduce the production of biologically active 3-hydroxykynurenine (3HK), which is a byproduct of KMO activity and contributes to tissue damage."

      Covered on